Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

References

• Kurzrock R, Kantarjian H, Talpaz M. Chronic myelogenous leukemia in chronic phase. Curr Treat Options Oncol 2001; 2: 245–252
   PubMedGoogle Scholar
• Cortes J E, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996; 100: 555–570
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Talpaz M, Kantarjian H M. Current therapy of chronic myelogenous leukemia. Intern Med 2002; 41: 254–264
   PubMed Web of Science ®Google Scholar
• Brodsky I, Biggs J C, Szer J, Crilley P, Atkinson K, Downs K, et al. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update. Semin Oncol 1993; 20: 27–31, Quiz 32
   PubMed Web of Science ®Google Scholar
• Alimena G, Morra E, Lazzarino M, Liberati A M, Montefusco E, Inverardi D, et al. Interferon α-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–647
   PubMed Web of Science ®Google Scholar
• Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Smith T L, O'Brien S, Beran M, Pierce S, Talpaz M, the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254–261
   PubMed Web of Science ®Google Scholar
• Ozer H, George S L, Schiffer C A, Rao K, Rao P N, Wurster-Hill D H, et al. Prolonged subcutaneous administration of recombinant α 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975–2984
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H M, McCredie K, Trujillo J M, Keating M J, Gutterman J U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon α A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Stone R M. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004; 9: 259–270
   PubMed Web of Science ®Google Scholar
• Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004; 8(iii)1–120
   Google Scholar
• Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on chronic myeloid leukemia. J Clin Oncol 2005; 23: 4100–4109
   PubMed Web of Science ®Google Scholar
• O'Dwyer M E, Mauro M J, Druker B J. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 2002; 53: 369–381
   PubMed Web of Science ®Google Scholar
• Silver R T, Woolf S H, Hehlmann R, Appelbaum F R, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517–1536
   PubMed Web of Science ®Google Scholar
• Bilhou-Nabera C, Marit G, Gharbi M J, Salzes S, Mahon F X, Broustet A, Reiffers J, Bernard P. Chronic myelocytic leukemia patients achieving complete cytogenetic conversion under interferon α therapy: minimal residual disease follow-up. Leukemia 1995; 9: 2067–2070
   PubMed Web of Science ®Google Scholar
• Jonasch E, Haluska F G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34–55
   PubMed Web of Science ®Google Scholar
• Perry C M, Jarvis B. Peginterferon-α-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61: 2263–2288
   PubMed Web of Science ®Google Scholar
• Reddy K, Modi M, Pedder S. Use of peginterferon α-2a (40 KD) (pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002; 54: 571–586
   PubMed Web of Science ®Google Scholar
• Talpaz M, O'Brien S, Cortes J, Giles F, Rittweger K, Hooftman L, Rakhit A, Kantarjian H. Phase I study of pegylated-interferon a-2a (PEGASYS™) in patients with chronic myelogenous leukemia (CML). Blood 1999; 94(Suppl 1), 530a (abstract 2373)
   Google Scholar
• Motzer R J, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L. Phase I trial of 40-kd branched pegylated interferon α-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19: 1312–1319
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23(Suppl 1)23–28
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman S V, Rasenack J, Heathcote E J, Lai M Y, Gane E, et al. Peginterferon α-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–1672
   PubMed Web of Science ®Google Scholar
• Heathcote E J, Shiffman M L, Cooksley W G, Dusheiko G M, Lee S S, Balart L, et al. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–1680
   PubMed Web of Science ®Google Scholar
• Rasenack J, Zeuzem S, Feinman S V, Heathcote E J, Manns M, Yoshida E M, et al. Peginterferon α-2a (40 kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon α-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341–349
   PubMed Web of Science ®Google Scholar
• Motzer R J, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, et al. Phase II trial of branched peginterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002; 13: 1799–1805
   PubMed Web of Science ®Google Scholar
• Dummer R, Garbe C, Thompson J, Eggermont A M. A randomized, dose escalation study evaluating the safety, tolerability and efficacy of peginterferon α-2a (40 KD) in patients with metastatic malignant melanoma. Proc Am Soc Clin Oncol 2003; 22, Abstract 712
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, Allan N C, Baccarani M, Kluin-Nelemans J C, Alimena G, Steegmann J L, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Giles F J, O'Brien S M, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-α and chemotherapy. Hematol Oncol Clin North Am 1998; 12: 31–80
   PubMed Web of Science ®Google Scholar
• Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver R T, Tendler C. Pegylated recombinant interferon α-2b vs recombinant interferon α-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18: 309–315
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S, Cortes J E, Shan J, Giles F J, Rios M B, et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033–1041
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Chronic myelogenous leukemia. Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, Jenkintown, PA 2004
   Google Scholar
• Kantarjian H M, O'Brien S, Cortes J, Giles F J, Rios M B, Shan J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003; 98: 2636–2642
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian H, O'Brien S, Cohen P R, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon α therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401–2407
   PubMed Web of Science ®Google Scholar
• Tothova E, Kafkova A, Stecova N, Fricova M, Guman T, Svorcova E. Immune-mediated complications during interferon α therapy in chronic myelogenous leukemia. Neoplasma 2002; 49: 91–94
   PubMed Web of Science ®Google Scholar